Serum levels of IL-8 in chronic RHD

International Journal of Medical Science

© 2020 by SSRG - IJMS Journal

Volume 7 Issue 7

Year of Publication : 2020

Authors : Smita A. Deokar, Dr. Sucheta P. Dandekar

10.14445/23939117/IJMS-V7I7P104

How to Cite?

Smita A. Deokar, Dr. Sucheta P. Dandekar, "Serum levels of IL-8 in chronic RHD," SSRG International Journal of Medical Science, vol. 7,  no. 7, pp. 15-17, 2020. Crossref, https://doi.org/10.14445/23939117/IJMS-V7I7P104

Abstract:

Rheumatic heart disease (RHD) remains a serious public health problem in developing countries. The form of immune response after revelation to
streptococcus is one of the main factors of the rheumatic inflammatory process, making it essential to identify the patients who present a higher risk of
disease progression. Inflammation plays an important role in rheumatic heart disease. Very few studies are done so far concerning serum interleukin-
8 (IL-8) levels in chronic rheumatic heart disease (RHD) patients. This study aimed to determine if serum IL-8 can be used as a biomarker of RHD. The study employed 20 chronic RHD patients and 20 healthy age and sex-matched controls for serum analysis of IL-8 on Enzyme-Linked Immunosorbent Assay (ELISA). Study results show that there is a significant difference (p<0.0005) in the IL-8 levels of chronic RHD patients [median (IQR) 104.3(121.3) pg/mL] from controls [median (IQR) 18.6 (72.0) pg/mL]. At present very less is known about the role of IL-8 in chronic RHD, the study findings show that IL-8 which a pro-inflammatory cytokine can be used as a biomarker in chronic RHD patients.

Keywords:

Interleukin-8, cardiovascular disease, ELISA, proinflammatory cytokine, rheumatic fever, rheumatic heart disease.

References:

[1] I. M. Velásquez, “The association of inflammatory biomarkers with cardiovascular events : a long and winding path,” 2015.
[2] Smita Amol Deokar, Sucheta P. Dandekar, “Role of serum interleukin-6 in heart failure,” Int. J. Adv. Med., vol. 5, no. 4, pp. 936–940, 2018.
[3] M. D. Huffman and D. Prabhakaran, “Heart failure: epidemiology and prevention in India.,” Natl. Med. J. India, vol. 23, no. 5, pp. 283–288, 2010.
[4] S. C. Leao, M. R. M. Lima, H. M. do Nascimento, S. Octacilio-Silva, and T. M. de A. Rodrigues, “IL-10 and ET-1 as biomarkers of rheumatic valve disease.,” Rev Bras Cir Cardiovasc, vol. 29, no. 1, pp. 25–30, 2014.
[5] L. Guilherme et al., “Rheumatic heart disease: Proinflammatory cytokines play a role in the progression and maintenance of valvular lesions,” Am. J. Pathol., vol. 165, no. 5, pp. 1583–1591, 2004.
[6] Z. Kronfol, “Cytokines and the Brain: Implications for Clinical Psychiatry,” Am. J. Psychiatry, vol. 157, no. 5, pp. 683–694, 2000.
[7] A. Ozeren et al., “Levels of serum IL-1beta, IL-2, IL-8 and tumor necrosis factor-alpha in patients with unstable angina pectoris.,” Mediators Inflamm., vol. 12, no. 6, pp. 361–5, 2003.
[8] D. Sika-paotonu, A. Beaton, A. Raghu, A. Steer, and J. Carapetis, “Acute Rheumatic Fever and Rheumatic Heart Disease,” Streptococcus pyogenes Basic Biol. to Clin. Manifestations, pp. 1–57, 2017
[9] N. Kutukquler and N. Narin, “Plasma Interleukin-7 ( IL-7 ) and IL-8 Concentrations in Acute Rheumatic Fever and Chronic Rheumatic Heart Disease,” vol. 7, no. Table I, pp. 383–385, 1995.